PHAT stock

Phathom Pharmaceuticals Inc (PHAT) support and resistance · rev $132.6M

Phathom Pharmaceuticals Inc (PHAT) is a biotechnology company listed on US.

This page maps Phathom Pharmaceuticals Inc (PHAT) support and resistance from cached range and valuation — not a live tape and not a trade alert.

Latest reported PHAT revenue for 2026-06-30 was $132.6M. Net income was -$48.0M. PHAT currently screens at market cap $622.7M.

PHAT currently screens at market cap $622.7M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.

A new PHAT 8-K or 10-Q can move the levels that matter more than a drawing on a chart.

Not investment advice. Use the PHAT quote page for the session range and the stock page for the full model.

Not investment advice.

Full PHAT analysis